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Hypersensitivity reactions to titanium (Ti) are very rare. Thus, we assessed the proinflammatory response and also potential
tolerance favoring in vitro reactivity of human blood lymphocytes and monocytes (PBMC) to Ti in healthy individuals (14 without,
6 with complication-free dental Ti implants).The proliferation index (SI) in lymphocyte transformation test (LTT) and production
of cytokines linked to innate immune response (IL-1𝛽, IL-6, and TNF𝛼) or immune regulation (IL-10) were assessed in response to
TiO
2
particles or Ti discs. In both groups, the Ti-LTT reactivity was not enhanced (e.g., SI < 3). The control antigen tetanus toxoid
(TT) gave adequate reactivity (median SI individuals without/with implant: 20.6 ± 5.97/19.58 ± 2.99). Individuals without implant
showed higher cytokine response to Ti materials than individuals with symptom-free implants; for example, TiO
2
rutile particle
induced increase of IL-1𝛽 70.27-fold/8.49-fold versus control medium culture. PBMC of 5 of the 6 individuals with complication-
free Ti implants showed an ex vivo ongoing production of IL-10 (mean 4.18 ± 2.98 pg/mL)-but none of the 14 controls showed
such IL-10 production.Thus in vitro IL-1𝛽-, IL-6-, and TNF-𝛼 production reflects “normal” unspecific immune response to Ti.This
might be reduced by production of tolerogenic IL-10 in individuals with symptom-free Ti dental implants.
1. Introduction
Cutaneous hyperreactivity to metals is common with nickel
(Ni) and to a lesser extent cobalt (Co) and chromium (Cr)
being typical elicitors. The underlying mechanism is a T-
lymphocyte driven antigen-specific delayed type hypersen-
sitivity [1]. The general population has repeated contact to
titanium (Ti) in the form of TiO
2
in paints and whitening
agents, in many sunscreens and skin care products. In the
industrial field, many workplaces include the handling of
Ti, as it is used in metallurgic, pharmaceutical, and food
industries. Furthermore, Ti-based materials are widely used
in orthopaedic surgery and dental implantology, as they offer
a fast osseointegration. However, only very few case reports
or small case series exist describing potential hypersensitivity
reactions to Ti, for example, axillary dermatitis to a Ti lactate
containing antitranspirant; local eczema or inflammatory
granulomatous reactions to Ti-based pacemakers; impaired
wound/fracture healing upon osteosynthesis; and loosening
of hip arthroplasty in association with peri-implant Ti wear
particles and patients showing skin test reactivity to a Ti
containing ointment [2–6]. On the other hand, patients prior
to implantation or already having Ti-based implants may be
concerned by reports on the risk of local or systemic adverse
health effects. Some authors have reported high frequency of
“hyperreactors” against Ti using lymphocyte transformation
test (LTT) [7]. However, there is a controversial discussion
regarding Ti related immune reactivity [8, 9] since the LTT
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may at the most indicate sensitization leaving its clinical
significance open [10–12]. Furthermore, LTT has so far been
accepted for and is restricted to cases of suspected Ni,
beryllium, or drug hypersensitivity [10].
Although Ti has been regarded as “biologically inert,”
more recent research has shown that Ti-based implants
undergo biocorrosion and release metal ions and particles
into surrounding tissues. Various mechanisms, including
mechanical wear—particularly in arthroplasty prostheses—
and electrochemical corrosion, may account for such local
metal release and potential dissemination [13–15]. It seems
that systemic dissemination of Ti ions is not limited to hip
arthroplasty but may encompass also patients with osteosyn-
thesis (e.g., intramedullary nails) [16–18].
The formation of periprosthetic osteolytic lesions is a
major clinical problem in joint replacement. The innate
immunity has been implicated to be the predominate
responding mechanism to wear particles, and, correspond-
ingly, TNF𝛼, IL-6, and especially IL-1𝛽 expression has been
found in areas surrounding failed arthroplasty [13, 19, 20].
In addition to soluble and particulate materials derived
from metal implants made of CoCrMo alloy [21], Ti wear
particles have also been shown to induce IL-1𝛽 secretion
through activation of the inflammasome complex [22].
A similar danger signal-related release of mediators like
IL-1𝛽 or IL-6 has also been observed in Ti dental implant
patients with peri-implantitis [23].
Assuming that Ti is released from implants, the next
question would be to quantify the “normal” inflammatory
mediator production in response to it. To answer this ques-
tion, our investigations addressed two aims. The first aim
is, to assess the inflammatory mediator production and LTT
reactivity of human lymphocytes and monocytes collected
from healthy individuals and exposed to Ti particles and
discs in vitro. Thus, the “normal” range of such response
in individuals without implant should be established. The
second aim is, to investigate potential variations of this
response in healthy individuals with symptom-free Ti dental
implants.
2. Materials and Methods
2.1. Titanium Materials. Since metallic Ti spontaneously
oxidises to titanium dioxide in air or water and forms a pro-
tective surface layer against further oxidation, commercially
pure titanium dioxide (TiO
2
) particles (Sigma, Deisenhofen,
Germany) were obtained having anatase or rutile as the
main crystallographic structure: the anatase particles had
a size <44 𝜇m (product no. T8141) and the rutile particles
a size <5 𝜇m (product no. 224227). Particles of these two
different size ranges were chosen according to their potential
of different inflammasome complex activation (e.g., “frus-
trated phagocytosis” generated by large-sized particles or
“endosomal destabilization” by readily phagocytized smaller
particles) [24, 25]. After having been autoclaved, the particles
were suspended in sterile cell culture medium for subsequent
studies. The anatase particles tended to agglomerate in the
cell culture medium (Figure 1). In addition to TiO
2
particles,
Figure 1: Ti-particles in anatase structure, mostly agglomerated.
Ti discs were used. They consisted of commercially available
pure Ti (grade 4) and were supplied by Nobel Biocare with a
diameter of 6mm and a thickness of 1.75mm. Three surface
modifications of the discs were applied: as-machined (MA),
spark anodized (SA), and sand blasted and acid etched
(SBA). The surface roughness was measured with a white
light interferometer and amounted 0.5 𝜇m for the machined
surface, 1.25 𝜇m for the spark anodized surface, and 1.75𝜇m
for the sand blasted and etched surface modifications.
The discs were cleaned and sterilized by gamma irradia-
tion. They were sent to us in 96% ethanol. Before using them
for cell culture experiments, the discs were removed from the
ethanol and air-dried in a sterile environment.
2.2. Blood Donors. A total of 20 healthy nonsmoking (12m,
8 f; 21–62 years) volunteers were recruited for this project
among the staff of the University Clinic to minimize poten-
tial confounding factors. All participants were healthy as
assessed by regular occupationalmedicine checkup including
examination of systemic infectious diseases; there was no
uptake of immunomodulating/immunosuppressive medica-
tion; there was no previous or ongoing immunomodulatory,
for example, hyposensitization immunotherapy; in the two
individuals with atopy, blood samplingwas done in the pollen
free season. All individuals were nonsmokers. The study was
approved by the local ethics committee. Six of the individuals
had symptom-free Ti dental implants; for example, there
were no complaints and also no signs of inflammation upon
dentist’s check. Fourteen did not have dental implants. An
overview of the participant characteristics is given in Table 1.
For the in vitro experiments, 60mL of heparinised blood was
taken by peripheral venous puncture.
2.3. Cell Preparation and Stimulation. Peripheral blood
mononuclear cells (PBMC) were isolated from the freshly
drawn blood samples by Ficoll-Paque (Pharmacia, Uppsala,
Sweden) density gradient centrifugation. The PBMC were
then resuspended at 1 × 106/mL in supplemented culture
medium (Biochrome, Berlin, Germany) containing autolo-
gous serum and were stimulated in quadruplicate culture
over 6 days under the following conditions: culture medium
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Table 1: Characteristics of the blood donors.
Initials Gender Age Ti dental implant Other dental materials CMI Patch test Smoker Atopy
Number Since
H. T. m 45 1a 2006 Crown; ceramic; metal No n.d. No No
T. B. m 21 3b 2007 No No n.d. No No
K. C. m 41 1c 2003 Crown; resin; ceramic No n.d. No ra
K. H. m 49 1d 2009 Crown; ceramic; metal No n.d. No ra
F. M. m 56 1e 2006 Crown; ceramic; metal No Negative No No
S. R. f 62 6f 2005 Crown; ceramic No n.d. No No
S. L. f 25 None Resin; ceramic Yes Ni; Lan. No No
C. S. m 23 None No No Negative No ra; aa; ae
H. C. f 23 None No No Negative No No
P. M. f 24 None No No Negative No No
G. G. m 31 None No No n.d. No No
S. J. m 34 None Crown; resin; ceramic No Thiomer; Merc. No No
F. T. f 29 None No No n.d. No ra
A. A. m 34 None Ceramic; amalgame No n.d. No ra
F. K. m 46 None Crown; metal No n.d. No ra
N. J. m 33 None Crown; resin No n.d. No No
S. F. m 23 None Crown; metal No n.d. No No
E. R. f 30 None No No Negative No ra; ae; aa
B. P. f 43 None Crown; resin; ceramic; metal No Negative No No
R. C. f 35 None Crown; ceramic No n.d. No No
CMI: cutaneous metal intolerance; aa: allergic asthma; ra: rhinoconjunctivitis allergica; ae: atopic eczema.
Patch test reaction: Ni: nickel; Lan: lanolin; Thiomer: thiomersal; Merc: mercury-II-amidchloride; negative: no test reaction; n.d.: not done.
a,b,c,d,e,fImplant devices of different manufacturers (details known to the authors) made of pure titanium or TiAlVa alloy.
alone (negative control), of T-cell mitogen phytohemagglu-
tinin (PHA, Biochrom, Berlin, Germany) 2.4𝜇g/mL or the
recall antigen tetanus toxoid (TT, Chiron Behring, Berlin,





(anatase structure and rutile structure, 10−4M, 10−5M, Sigma,
Germany); and layering over titanium discs (3 variants, for
example, MA, SA, and SBA). One set of cultures was used to
obtain the conditioned supernatants. Here, instead of PHA
the pan T-cell cytokine stimulator phorbol-myristate-acetate
(PMA, Sigma, Munich, Germany; 150mmol) was added.The
other set was used for the proliferation assay.
2.4. Lymphocyte Proliferation Assay. To assess the prolif-
erative response of the PBMC cultured with Ti discs or
TiO
2
particles, cells were pulsed with 3H-thymidine for the
last 18 h after 5 days of culture (Amersham Biosciences,
Freiburg, Germany). In order to determine the incorporated
radioactivity, labelled cells were harvested, and a scintillation
counter was used. The proliferative response was expressed
as stimulation index (SI), which was calculated by the ratio of
mean counts per minute (cpm) of stimulated to unstimulated
cultures. A SI > 3 was regarded as positive [26].
2.5. Analysis of Cytokine Production. After the 6-day culture,
supernatants of the nonradioactive culture (pooled from each
of the duplicate experiments) were assayed for the presence of
pro-inflammatory cytokines mostly linked to innate immune
response, for example, IL-1𝛽, IL-6, and TNF-𝛼, and for the
antiinflammatory cytokine IL-10. Levels of these cytokines
were determined by use of fluorescent antibody marked
microparticles in a cytometric bead assay (BD Biosciences,
Heidelberg, Germany) and flow cytometry. In order to take
account of potential spontaneous or preexisting cytokine
liberation, the cytokine levels found upon stimulation were
put into relation to the baseline cytokine amount determined
in the culture with medium only (control without stimuli).
This relation is given as fold increase.
2.6. Statistical Analysis. All calculations for data assessment
were performed using SPSS software. For comparison of the
2 groups the Wilcoxon rank-sum test was used. 𝑃 < 0.05
was considered significant. Data are presented by box plot
indicating the 25th and 75th percentiles and the median. The
frequency of spontaneous IL-10 production was evaluated by
the use of the Fishers exact test.
3. Results
3.1. Proliferative Response in the LTT. As expected, increased
proliferation was seen to the T-cell stimulator PHA in both
groups (median SI in implant patients: 16.5 ± 6.24; median
SI in healthy controls without implant: 30.1 ± 5.66) reflecting
the absence of immunosuppressive influences and showing
adequate T-cell response. To assure that cells would properly
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Figure 2: Lymphocyte proliferation response of the PBMC of the 14 healthy individuals without titanium dental implants (open bar) and 6
blood donors with symptom-free titanium dental implants (closed bar). Reactivity to stimulation with titanium particles in rutile and anatase
structures (5 × 10−4M, 1 × 10−4M, 5 × 10−5M) ((a) and (b)), the three titanium metal discs (SBA, MA, and SA) (c) and to the controls (recall
antigen) tetanus toxoid (TT) and (pan T-cell mitogen) phytohemagglutinin (PHA), over 6 days. Stimulation index (SI) is given as ratio of
stimulated culture to unstimulated culture.
react to a protein recall antigen, we used tetanus toxoid
(TT) based on everybody’s previous vaccination-dependent
exposure to it. Accordingly, stimulation with TT was able
to induce a (specific) T-cellular proliferative response with
median SI of 20.6 ± 5.97 for healthy control subjects and
19.58 ± 2.99 for individuals with symptom-free Ti dental
implants. These data reflect a valid immunisation status to
TT in the individuals tested and a corresponding adequate
in vitro response. When assessing the LTT response to the
different Ti particles (rutile and anatase) and to the Ti
discs, the median SI always remained below the level of 3.
Thus, there was no enhanced T-lymphocytic proliferation in
both the individuals without and those with symptom-free
Ti dental implants. The respective data are summarized in
Figures 2(a)–2(d).
3.2. Cytokine Production. To determine whether in vitro
exposure to Ti particles or Ti metal discs was inducing
cytokines of an innate immune response, the levels of IL-
1𝛽, IL-6, and TNF-𝛼 were assessed. The respective results
are given in Figures 3(a)–3(c). Whereas the pan stimulator
PMA leads to high, comparable levels of IL-1𝛽, IL-6, and
TNF-𝛼 in both groups, there was—to a varying extent—a
reduced release of those cytokines from Ti exposed PBMC
of individuals with symptom-free Ti dental implants. For
example, for TiO
2
particles (rutile structure 5 × 10−5M), this
difference was for IL-1𝛽 70.27 ± 672.31median fold increase
(patients without implants) versus 8.49 ± 7.92 median fold
increase (patients with implant; 𝑃 < 0.05). With regard to
particles in general, rutile structure seemed to induce higher
response, which could be related to the smaller size and the
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Figure 3: Production of IL-1𝛽 (a), IL-6 (b), and TNF𝛼 (c) of PBMC of the 20 blood donors (14 healthy individuals without titanium dental
implants = open bar and 6 with symptom-free titanium dental implants = closed bar) after stimulation with titanium particles in anatase and
rutile structures (5 × 10−4M, 1 × 10−4M, 5 × 10−5M) and the three metal discs over 6 days. Fold increase versus stimulation with medium
alone is given.
higher surface-to-volume ratio of these particles compared
to the anatase particles. Within the three Ti disc variants,
“MA” gave a lower response of these three cytokines, which
could be due to the smaller surface area of the machined
discs compared to the “SA” or “SBA” discs. With regard to
TT, its specific recognition did not trigger danger signal
(inflammasome) related IL-1𝛽 release.
To show whether there was some modulation of (mono-
cytic) cytokine response to both Ti particles and disc surfaces
by the presence of autologous T-cells, ex vivo PBMC cultures
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Figure 4: Frequency (%) of spontaneous IL-10 production of PBMC
of the blood donors (6 with, 14 without dental Ti implant) after 6 day
culture with medium alone. ∗∗𝑃 < 0.001 (Fishers exact test).
Table 2: Spontaneous cytokine production by the ex vivo obtained
PBMC of the 20 individuals. Cytokine levels were assessed in super-
natants of unstimulated (e.g., only culture medium) 6 d cultures.
Individuals with titanium








IL-1𝛽 9.04 16.87 23.39 65.47
IL-6 688.33 1566.10 1909.8 4958.15
IL-10 4.18 2.98 0 0
TNF𝛼 1.02 1.93 1.75 4.52
were used. Furthermore, we compared PBMC of healthy
blood donors without exposure to Ti dental implants to those
of symptom free carriers of Ti dental implants. Since IL-
10 plays a crucial role in downregulation of inflammatory
responses, its expression was monitored. In the unstimulated
cultures IL-10 was only produced by PBMC derived from
symptom-free carriers of Ti dental implants. None of the 14
individuals without implant, but 5 of the 6 implant carriers
showed such basal IL-10 production (Table 2 and Figure 4).
These data indicate that there were already in vivo IL-10
generating, tolerance favoring cells in those individuals.
4. Discussion
Released Ti may be detected not only in tissues surround-
ing joint replacement, but also in regional lymph nodes
in association with Ti screws or mini plates [15, 27–29].
Ti is also encountered in tissues adjacent to dental Ti
implants, although not as extensive—and fretting maybe one
of the underlying mechanisms [30]. The wear particle related
macrophage activation stimulates the release of proinflam-
matory cytokines such as TNF-𝛼, IL-6, prostaglandin E2,
and IL-1𝛽 [31, 32]. These cytokines—particularly IL-1𝛽—
are considered to directly or indirectly mediate osteoclastic
differentiation and activation and ultimately bone resorption
[33]. The role of Ti in the induction of a IL-1-related peri-
implant inflammation with subsequent bone resorption has
been shown in animal (mice) models using intramedullary
Ti rod implantation and Ti particles introduced onto the
calvarium [20, 34].
In analogy to orthopaedic implants, many reasons and
risk factors for dental implant failure have been published,
including oral bacterial load, smoking, presence of diabetes
mellitus, or iatrogenic factors [35–38]. In contrast, the role
of hypersensitivity or proinflammatory cytokine response
to Ti is still a controversial issue [4, 9]. There are no
evaluated patch test preparations for skin testing in case
of suspected Ti hypersensitivity. In addition the sometimes
used TiO
2
preparation may produce unspecific reactions and
false positive patch test reactions due to impurities [39].
This might also be considered as differential etiology in
intolerance reactions to Ti materials [40]. Thus, the LTT
is sometimes used to look for Ti sensitivity. The LTT is
used for measurement of proliferation in PBMC cultures
in response to addition of antigens, to which sensitization
has occurred. However, in the present study, a significant
increase of SI response to TiO
2
particles or Ti-discs was
not observed. This is in accordance with experiments of
Park et al. showing that, in the local lymph node assay the
SI value did not increase to TiO
2
particles, but to eugenol
as positive control [41]. However it has been shown that
mouse and human macrophages respond to Ti particles
with the production of IL-1𝛽 [9, 22]. This IL-1𝛽-associated
response to Ti particles is associated with activation of the
NALP3 inflammasome.A similar cytokine response had been
already linked to inflammasome activation in the case of in
vitro response to silica crystals and aluminium salts [42].
In the murine model, Ti particle exposure leads to IL-1𝛽
mediated proinflammatory responses including neutrophil
recruitment and bone resorption [34]. In our study, we
hypothesized that proinflammatorymediator release, namely,
IL-1𝛽, IL-6, and TNF𝛼, would reflect a “normal” unspecific
response in patients exposed to Ti particles. We used PBMC
cultures to examine whether such mediator release could be
modulated by the presence of autologous T-lymphocytes.
Our results show that coculture of human PBMC with
either Ti particles or Ti discs leads to release of considerable
amounts of IL-1𝛽, IL-6, and TNF-𝛼. When using a typical
recall antigen (tetanus toxoid) such secretion of IL-1𝛽was not
seen. However, a reduced release of cytokines by PBMC was
observed in patients with symptom-free Ti dental implants.
We thus wondered if, by using PBMC, that is, in the presence
of T-lymphocytes, some regulatory mechanisms may be
demonstrable. When considering scenarios with produc-
tion of systemic proinflammatory mediators, for example,
early after surgery, cardiac arrest, or in sepsis patients,
anti-inflammatory mediators—namely IL-10 or IL-1𝛽Ra—
have been concomitantly found [43–45]. Martire-Greco and
coworkers investigated the effect of the presence of IL-10
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in the cultures of human neutrophils (PMN) subsequently
exposed to LPS and found that the TNFa and IL-8 secretion
was markedly attenuated upon addition of IL-10 to the
cultures [46]. With regard to our experiments, in contrast to
PBMC of the 14 individuals not yet exposed to Ti, those of
individuals with well tolerated Ti dental implants produced
the potent anti-inflammatory cytokine IL-10 in vitro. Five
of the 6 implant carriers showed PBMC with the basal
production of IL-10. As reported by Pinke et al., in their
investigation of unstimulated PBMC cultures from healthy
young individuals (20 to 50 years old), the large majority
showed no basal IL-10 production in vitro [47]. Thus, our
observation seems to be a relevant finding, as IL-10 has
an important role in the in vivo regulation in sense of a
negative feedback loop reducing the release of inflammatory
mediators and dampening an acute inflammatory response
[48–50]. There is, for example, also an increased expression
of IL-10 by PBMC of pregnant individuals with a proba-
ble role maintaining fetal tolerance [51, 52]. IL-10 is also
induced in circulating PBMC upon specific immunotherapy
with pollen allergens [53]. In general, many cells of the
innate and adaptive immune system may produce IL-10, and
even do so together with proinflammatory cytokines [54].
A recent paper has suggested, that, by understanding the
regulatory mechanisms for IL-10 expression, this cytokine
could be a therapeutic target to reduce inflammatory tissue
damage [54]. As IL-10 was found to be secreted from the
ex vivo obtained PBMC of individuals with symptom-free
Ti implants, it is tempting to speculate that IL-10 prevent
from peri-implant inflammation, even though peri-implant
inflammatory cytokine production may also be present in
healthy subjects without implant failure. Correspondingly,
Nowzari et al. concluded from their experiments that there
is an inevitable and ongoing spectrum of microorganisms
and interleukins around teeth and implants [55]. There is,
however, still controversy about the interplay and significance
of the different interleukins in crevicular fluid and peri-
implantitis [23]. At present, we know little about the immune
mechanisms leading to well-tolerated Ti dental implants,
but our results indicate that adaptive mechanisms may
exist. Future studies will determine which factors and cell
populations will add to this protective tolerance.
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